Compare Halliburton Company (HAL) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halliburton Company vs TransMedics Group Inc — how do they compare? Halliburton Company trades at $32.51 (market cap $27.14B), while TransMedics Group Inc trades at $77.34 (market cap $2.74B). The key difference: Halliburton Company is far larger — about 9.9× TransMedics Group Inc's market cap, and Halliburton Company pays a 2.09% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halliburton Company for 89 Days and TransMedics Group Inc for 24 Days on average.
| HAL | TMDX | |
|---|---|---|
Market Cap | $27.14B | $2.74B |
Volume | 11,258,156 | 949,331 |
Sector | Energy | Health |
52-Week High | $42.98 | $150.42 |
52-Week Low | $21.82 | $61.99 |
Typical Hold Time | 89 Days | 24 Days |
Enterprise Value | $33.29B | $3.13B |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Halliburton (HAL) trades at $32.57, up 2.58% today, with a bearish technical signal despite recent earnings beats. The company shows solid profitability with a 7.16% net income margin and 14.89% ROE, though revenue dipped slightly in 2025. Recent news highlights expansion in Venezuela and a new deepwater contract in Cyprus, signaling growth initiatives. Analyst consensus is strongly bullish with a $43.11 price target, but technical indicators and recent CFO stock sales introduce caution.
The outlook for HAL is mixed; strong analyst support and strategic contracts offer upside, but technical weakness and exposure to oil price volatility pose risks. Investors should weigh the company's solid fundamentals and growth projects against market sentiment and industry cyclicality for balanced decision-making.
TransMedics Group (TMDX) trades at $80.69, down 0.47% on the day, amid a bearish technical signal and mixed earnings performance. The company reported strong revenue growth to $605.49M in 2025 with a net income margin of 22.69%, but recent quarters have seen earnings misses. Analyst sentiment remains positive with a consensus price target of $99.75 and a 69% buy rating, though news flow includes investigations into fiduciary duties.
The outlook balances robust fundamentals against near-term headwinds. Upside potential exists from the high analyst target and strong profitability metrics like a 36.28% ROE, but risks include earnings volatility, margin pressure, and ongoing legal scrutiny. The stock's current valuation at a P/E of 20.47 offers a reasonable entry if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
